Limitations of CAR-T-Cell Therapy in Hematologic Malignancies: Focusing on Antigen Escape and T-Cell Dysfunction
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26199669 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Yanyu Lin und 8 weiteren Autor:innen. Beteiligte Einrichtung: Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Qishan Campus, Fujian Normal Univ…. Hauptthemen laut MEDLINE: Hematologic Neoplasms, Immunotherapy, Adoptive, T-Lymphocytes, Receptors, Chimeric Antigen. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 222 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Fujian Province, Innovation of Science and Technology, Fujian Province.
Abstract (Originalsprache)
Chimeric antigen receptor T (CAR-T)-cell therapy has revolutionized the treatment of hematological malignancies, yet long-term efficacy remains constrained by antigen escape and T-cell dysfunction. Recent advances have rapidly elucidated the molecular underpinnings of antigen escape mechanisms and intrinsic T-cell dysfunction, revealing novel vulnerabilities in current CAR-T paradigms. In this review, we discuss the limitations of CAR-T-cell therapy in hematological malignancies, particularly regarding antigen escape mechanisms and T-cell dysfunction. It is noteworthy that in recent years, multi-targeted CAR-T and engineered CAR-T cells have demonstrated promising clinical efficacy in overcoming drug resistance and relapse in hematological malignancies. Here, we also discuss emerging approaches to enhance the efficacy of CAR-T-cell therapy, including advanced CAR-T-cell engineering techniques, the identification of novel therapeutic targets, and the development of multi-targeted CAR-T-cell strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fujian Key Laboratory of Innate Immune Biology, Biomedical Research Center of South China, College of Life Science, Qishan Campus, Fujian Normal University, Fuzhou 350117, China.
- State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen 361102, China.
ORCID-Profile: Jianhui Wei, Yangkun Shen, Qi Chen
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Fujian Province
- Innovation of Science and Technology, Fujian Province
- Fujian Cancer Hospital Subject
Zitieren
APA
Lin, Y., Luo, S., Wei, J., Lin, S., Wang, D., Zhao, X., Feng, Z., Shen, Y., & Chen, Q. (2025). Limitations of CAR-T-Cell Therapy in Hematologic Malignancies: Focusing on Antigen Escape and T-Cell Dysfunction. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26199669
Vancouver
Lin Y, Luo S, Wei J, Lin S, Wang D, Zhao X, et al. Limitations of CAR-T-Cell Therapy in Hematologic Malignancies: Focusing on Antigen Escape and T-Cell Dysfunction. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26199669
BibTeX
@article{Lin2025,
author = {Lin, Yanyu and Luo, Shuqi and Wei, Jianhui and Lin, Shujin and Wang, Dawei and Zhao, Xiangqian and Feng, Zexin and Shen, Yangkun and Chen, Qi},
title = {Limitations of CAR-T-Cell Therapy in Hematologic Malignancies: Focusing on Antigen Escape and T-Cell Dysfunction},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26199669}
}
EUVIMED